We are a diverse team with deep knowledge of the healthcare and neurology space and expertise in biomedical research, clinical practice and business/finance.


Chief Executive Officer, Founder

Kent Werner is a board-certified neurologist and neuroscientist.  He holds Assistant Professor appointments in the Departments of Neurology at the Uniformed Services University and adjunct at Johns Hopkins University. He has 14 years of experience in biomedical research and seven years in clinical training. Kent received his MD and PhD in Cellular and Molecular Medicine in the department of Neuroscience in 2012 at the Johns Hopkins University under Dr. Solomon Snyder. His areas of research include  neurodegenerative conditions to include dementia and traumatic brain injury and their relationship to sleep.




Christopher served in the US Army Special Forces (Green Berets) for over seven years, where he built high-performance teams in chaotic and fluid environments. He holds an MBA from Johns Hopkins Carey Business School, where he specialized in strategic marketing and risk management, and has studied data science at the Johns Hopkins School of Public Health.




Sean has over 10 years of experience in life science research. He is currently Director of Business Development & Alliances with Johns Hopkins Technology Ventures where he helps to identify and foster strategic partnerships with life science companies to accelerate academic innovation. Sean received an MS in Biotechnology (2008) and PhD in Microbiology and Immunology (2014) from the Johns Hopkins University.


Yvonne Angell, PHD

Vice President of Discovery

Yvonne has over 16 years of experience in the pharmaceutical industry. She has led research teams at Eli Lilly, Wyeth, Affymax, Ipsen Bioscience and is currently working on consulting projects through her own consulting firm, Picotide Technologies. Her primary expertise is in design, synthesis and lead optimization of novel peptides, peptidomimetics and peptide conjugates. Yvonne received her PhD in Medicinal Chemistry at the University of Wisconsin-Madison and post-doctoral work at the University of Minnesota. 


Ryan SpanglER, BS

Corporate Strategist

Ryan has over 5+ years of research experience in drug development and diagnostics from the NIH and Broad Institute of MIT and Harvard. At the Broad, he currently is a Research Associate developing systematic ways to repurpose existing small molecules for new disease indications. Ryan has been instrumental in Cogentis’s fundraising, business development, and scientific direction.


Sean Berkowitz, MD Candidate

Corporate Strategist

Sean is currently an MD candidate at Vanderbilt University with neuroscience research expertise from Duke University and the National Institutes of Health.